Degarelix available for prostate cancer

Degarelix approved for advanced prostate cancer
Degarelix approved for advanced prostate cancer
Degarelix (from Ferring Pharmaceutical), an injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, is available for the treatment of hormone sensitive advanced prostate cancer. Clinical trials demonstrated its effectiveness in reducing and sustaining castrate levels of testosterone, a hormone that stimulates prostate cancer growth.

Presently, a tradename is still pending for degarelix.  It is available in 80mg and 120mg vials of powder for reconstitution.  

For more information call (888) FERRING or visit www.ferringusa.com.